Alimera Sciences (NASDAQ:ALIM) Rating Lowered to Hold at StockNews.com

Alimera Sciences (NASDAQ:ALIM) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Separately, Maxim Group started coverage on Alimera Sciences in a report on Monday, March 25th. They issued a “buy” rating and a $10.00 price target for the company.

Alimera Sciences Stock Performance

Shares of Alimera Sciences stock opened at $3.52 on Friday. Alimera Sciences has a 52 week low of $1.56 and a 52 week high of $4.38. The company has a quick ratio of 2.31, a current ratio of 2.39 and a debt-to-equity ratio of 1.40. The stock’s fifty day moving average is $3.76 and its two-hundred day moving average is $3.60. The company has a market capitalization of $184.27 million, a PE ratio of -1.63 and a beta of 1.18.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). The company had revenue of $26.31 million for the quarter, compared to analysts’ expectations of $25.10 million. Alimera Sciences had a negative return on equity of 130.90% and a negative net margin of 24.93%. During the same quarter last year, the company earned ($0.54) earnings per share. As a group, analysts expect that Alimera Sciences will post 0.03 earnings per share for the current year.

Institutional Trading of Alimera Sciences

A number of large investors have recently made changes to their positions in ALIM. Millennium Management LLC acquired a new stake in shares of Alimera Sciences in the 4th quarter valued at about $32,000. Osaic Holdings Inc. acquired a new stake in shares of Alimera Sciences in the 2nd quarter valued at about $34,000. Tower Research Capital LLC TRC boosted its position in shares of Alimera Sciences by 291.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 8,937 shares during the period. Northern Trust Corp acquired a new stake in shares of Alimera Sciences in the 4th quarter valued at about $61,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Alimera Sciences in the 4th quarter valued at about $86,000. 99.83% of the stock is owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).